As more cell and gene therapies win FDA approval, a persistent and underappreciated bottleneck has emerged well beyond the clinical trial and regulatory questions: actually manufacturing enough product to meet eligible patient demand. Unlike traditional pharmaceutical manufacturing, which can scale relatively predictably through larger production runs, cell and gene therapy manufacturing faces structural constraints that don't simply resolve with more capital investment.
Why Personalized Manufacturing Doesn't Scale Like Traditional Drugs
Autologous cell therapies — those manufactured from a specific patient's own cells, including approved CAR-T and sickle cell gene therapies — are inherently limited to a batch size of one per patient. There's no equivalent to a pharmaceutical company simply running a larger production batch to meet higher demand; each patient's treatment requires its own dedicated manufacturing slot, quality testing, and release process, fundamentally limiting how many patients a given manufacturing facility can treat in a given period regardless of capital investment in additional equipment.
The Viral Vector Bottleneck
Many gene and cell therapies rely on modified viruses (viral vectors) to deliver genetic material into target cells — a specialized manufacturing process requiring highly controlled bioreactor production, extensive purification, and rigorous quality testing to ensure the vector is both effective and safe. Viral vector manufacturing capacity has historically been a genuine industry-wide bottleneck, with demand from the growing number of approved and pipeline therapies outpacing the specialized manufacturing capacity available, leading some developers to build dedicated in-house manufacturing capability rather than relying entirely on third-party contract manufacturers facing their own capacity constraints.
The Specialized Workforce Shortage
Cell and gene therapy manufacturing requires a highly specialized technical workforce — trained in cleanroom bioprocessing, quality control specific to biological products, and the particular regulatory documentation requirements governing cell and gene therapy manufacturing — that has not grown fast enough to match industry demand. This workforce shortage compounds the physical manufacturing capacity constraint, since even facilities with adequate equipment can be limited by available trained personnel to actually operate that equipment at full capacity.
Quality Failures and Batch Loss
Given the biological complexity and multi-week manufacturing timeline involved, a meaningful share of manufacturing runs fail to meet release specifications and cannot be used — a genuine problem when the starting material is a specific patient's own cells, since a failed batch may mean the patient needs to undergo a second, delayed collection and manufacturing attempt, with real clinical consequences for patients whose disease is actively progressing during that delay.
Allogeneic ("Off-the-Shelf") Therapy as a Potential Solution
A significant area of active development involves allogeneic cell therapies — manufactured from healthy donor cells rather than the individual patient's own cells, engineered to avoid immune rejection, and potentially manufacturable in larger batches that could then be available "off the shelf" for multiple patients rather than requiring individualized manufacturing for each. If this approach proves clinically successful and scalable, it could meaningfully address the core batch-of-one manufacturing constraint that limits current autologous therapy capacity — though allogeneic approaches remain earlier in clinical development than the currently approved autologous therapies.
Conclusion
Manufacturing capacity, not clinical science or regulatory approval, has increasingly become the binding constraint on how many eligible patients can actually access approved cell and gene therapies. Addressing that constraint will likely require continued investment in specialized manufacturing infrastructure, workforce training, and potentially a shift toward more scalable allogeneic treatment approaches over the coming years.
